Two classes of newer anti-hyperglycemic agents can reduce CV risk and events in patients with T2D, namely glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors
In SUSTAIN-6, patients on semaglutide experienced an average 4 mmHg greater systolic drop than placebo after 30 weeks, independent of weight loss (see the SUSTAIN-6 trial publication )
The lower abdomen, flanks, and lower back regions where fat tends to accumulate and persist often show the most dramatic improvement
The upcoming option for the carnitine-based weight loss supplement will feature a classic Miami Vice flavor combination, bringing together coconut with the fruity tastes of strawberry and pineapple.
The exact maintenance dose can vary depending on your goals, how well you tolerate semaglutide GLP-1, and how your body responds over time
The standard escalation protocol exists because the body needs time to adjust to GLP-1 receptor activation